Have you assessed how the international operations of Dentsply International (XRAY) performed in the quarter ended March 2025? For this dental products manufacturer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential. Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends. While delving into XRAY's performance for the past quarter, we observed some fascinating trends in the revenue from its foreign segments that are commonly modeled and observed by analysts on Wall Street. The recent quarter saw the company's total revenue reaching $879 million, marking a decline of 7.8% from the prior-year quarter. Next, we'll examine the breakdown of XRAY's revenue from abroad to comprehend the significance of its international presence. Unveiling Trends in XRAY's International Revenues During the quarter, Europe contributed $362 million in revenue, making up 41.18% of the total revenue. When compared to the consensus estimate of $356.44 million, this meant a surprise of +1.56%. Looking back, Europe contributed $408 million, or 45.08%, in the previous quarter, and $376 million, or 39.45%, in the same quarter of the previous year. Rest of World accounted for 24.46% of the company's total revenue during the quarter, translating to $215 million. Revenues from this region represented a surprise of +12.67%, with Wall Street analysts collectively expecting $190.83 million. When compared to the preceding quarter and the same quarter in the previous year, Rest of World contributed $238 million (26.30%) and $221 million (23.19%) to the total revenue, respectively. Projected Revenues in Foreign Markets It is projected by analysts on Wall Street that Dentsply will post revenues of $927.9 million for the ongoing fiscal quarter, a decline of 5.7% from the year-ago quarter. The expected contributions from Europe and Rest of World to this revenue are 40.5% and 22.5%, translating into $375.96 million and $208.34 million, respectively. Story Continues For the full year, the company is expected to generate $3.63 billion in total revenue, down 4.3% from the previous year. Revenues from Europe and Rest of World are expected to constitute 40.4% ($1.47 billion) and 22.7% ($823.78 million) of the total, respectively. The Bottom Line Relying on global markets for revenues presents both prospects and challenges for Dentsply. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook. In an era of growing international interdependencies and escalating geopolitical disputes, Wall Street analysts are vigilant in tracking these trends for businesses with a global reach, in order to refine their predictions of earnings. It should be noted, however, that a multitude of other elements, such as a company's domestic position, also play a significant role in shaping the earnings forecasts. At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short -term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price. With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance. Dentsply, bearing a Zacks Rank #3 (Hold), is expected to mirror the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Dentsply's Recent Stock Market Performance Over the preceding four weeks, the stock's value has appreciated by 28.1%, against an upturn of 9.1% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts Dentsply among its entities, has appreciated by 1.4%. Over the past three months, the company's shares have seen a decline of 8.6% versus the S&P 500's 3.1% decline. The sector overall has witnessed a decline of 8.7% over the same period. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DENTSPLY SIRONA Inc. (XRAY):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Dentsply (XRAY) Reliance on International Sales: What Investors Need to Know
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...